Active Surveillance Preserves Quality of Life in 2,550 Prostate Cancer Patients as 3-Year Survival Tops 99%
Updated
Updated · VUMC Reporter · Jun 10
Active Surveillance Preserves Quality of Life in 2,550 Prostate Cancer Patients as 3-Year Survival Tops 99%
3 articles · Updated · VUMC Reporter · Jun 10
Summary
A 2,550-man study found low-risk localized prostate cancer patients who chose active surveillance kept better quality of life while posting more than 99% three-year survival.
The finding addresses a central trade-off for men weighing treatment, as surgery and radiation can bring significant side effects despite similarly excellent short-term cancer survival.
Published March 21 in the Journal of the American Medical Association, the study compared contemporary surgery, radiation and active surveillance to help guide treatment decisions.
David Penson said men with low-risk prostate cancer should discuss active surveillance with their physicians, underscoring a broader shift toward avoiding overtreatment when outcomes are comparable.
With equal progress in cures and care, is the future of cancer treatment eradication or chronic management?
A decade later, have the 'promising' cancer drugs from 2017 become cures or clinical dead ends?
If gut bacteria can architect cancer, could engineered microbes become the new front in oncology?
Active Surveillance for Low-Risk Prostate Cancer: Long-Term Outcomes, Patient Impact, and Innovations Shaping 2026
Overview
Active surveillance (AS) is now the preferred approach for managing low-risk prostate cancer, as it reduces treatment-related side effects and improves quality of life without compromising cancer control. Supported by current guidelines, AS helps patients avoid unnecessary harm from overtreatment while still benefiting from early cancer detection. This strategy is also being considered for some intermediate-risk cases with favorable features. The success of AS relies on careful patient selection and regular monitoring, ensuring that most slow-growing cancers are safely observed and only treated if they show signs of progression.